Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pruvonertinib in Advanced NSCLC with EGFR Mutations
NCT05767866Phase 2Unknown
- Sponsor
- Suzhou Puhe Biopharma
- Start
- Mar 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pruvonertinib in non-small cell lung cancer (NSCLC), sponsored by Suzhou Puhe Biopharma. Status: unknown.
02
Drugs
pruvonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05767866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767866.